FOXO TECHNOLOGIES INC. ANNOUNCES ACQUISITION AGREEMENT TO ACQUIRE VECTOR BIOSOURCE INC.

Core Viewpoint - FOXO Technologies Inc. has signed a stock purchase agreement to acquire Vector Biosource Inc., a provider of information, data, and biospecimen sourcing for the biotechnology and pharmaceutical research industries, with expectations of significant growth post-acquisition [1][2]. Financial Summary - Vector generated approximately $225,000 in net revenues for the second quarter of 2025, equating to an annual run rate of about $0.9 million [1]. - The expected purchase price for Vector includes $500,000 in cash, 60,000 shares of Series E Preferred Stock valued at $1.5 million, warrants for $2 million of common stock at a 10% premium, and up to an additional 80,000 shares of Series E Preferred Stock contingent on achieving certain milestones [2]. Strategic Intent - The acquisition is viewed as a strategic move to enhance FOXO's position in the healthcare services sector, with plans for aggressive expansion through organic growth and potential acquisitions [2]. - FOXO has committed to funding up to $1.2 million for Vector's growth initiatives, indicating a strong belief in the potential synergies and growth opportunities that the partnership will create [2]. Company Overview - FOXO Technologies operates three subsidiaries: Rennova Community Health, which includes a critical access hospital; Myrtle Recovery Centers, a behavioral health facility; and FOXO Labs, a biotechnology company focused on health and lifespan improvement [3][4].